Rick N. EMPLICITI patient Ready to get started

Rick N. EMPLICITI patient Ready to get started

PICTURE YOUR IMMUNE SYSTEM AT WORK AGAINST MULTIPLE MYELOMA Rick N. EMPLICITI patient My body taking on multiple myeloma What is EMPLICITI? EMPLICITI is a prescription medicine used to treat multiple myeloma in combination with other medications: EMPLICITI (elotuzumab) + REVLIMID (lenalidomide) + dexamethasone Remember to read the safety information for the other medications you are receiving. EMPLICITI is for patients who have received one to three prior treatments for their multiple myeloma. EMPLICITI is for adults. The safety and effectiveness of EMPLICITI has not been studied in children. What are the serious side effects of EMPLICITI? Infusion reactions can happen during your EMPLICITI infusion or within 24 hours after your infusion. Symptoms of an infusion reaction may include: fever chills rash trouble breathing dizziness light-headedness Before every EMPLICITI infusion, your healthcare team will give you medications to help reduce the risk of infusion reactions. If you have an infusion reaction while receiving EMPLICITI, your healthcare provider will slow or stop your infusion and treat your reaction. If you have a severe infusion reaction your healthcare provider may stop your treatment completely. Call your healthcare provider or get medical help right away if you have any of the above symptoms after your infusion with EMPLICITI. Please read more Important Facts about EMPLICITI, including serious side effects, on pages 15-16. 2

This guide explains treatment with EMPLICITI and how it may help you. The information in this treatment guide should not replace talking to your healthcare team. If you have questions about your treatment, be sure to talk with your doctor or nurse. For additional questions or concerns, call 1-844-EMPLICITI (1-844-367-5424) 8 am to 8 pm ET, Monday to Friday, or visit Empliciti.com. What are the serious side effects of EMPLICITI? (cont d) EMPLICITI may cause side effects, some of which can be serious. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI. Infections may develop in patients who receive EMPLICITI with REVLIMID (lenalidomide) and dexamethasone, and can be serious. Symptoms of an infection may include: fever flu-like symptoms cough shortness of breath burning with urination painful skin rash Call a healthcare provider right away if you have any of the signs and symptoms of an infection. Please read more Important Facts about EMPLICITI, including serious side effects, on pages 15-16. Unless otherwise indicated as an EMPLICITI patient, individuals depicted are models used for illustrative purposes only. 3

TABLE OF CONTENTS What is immunotherapy? How does EMPLICITI work? How was EMPLICITI studied? How might EMPLICITI help me? What are some possible side effects of EMPLICITI? What can I expect at my EMPLICITI appointments? What are some treatment tips for EMPLICITI? What do I need to know about my treatment schedule? What are the Important Facts about EMPLICITI? Where can I find more support? Glossary * 5 5 7 9 10 12 13 14 15 17 19 * All words in yellow boxes are defined in the glossary. 4

immunotherapy Angela B. EMPLICITI patient What can it do for me? Immunotherapy is a type of treatment that works with your immune system to help control certain cancers. It is different because it is not surgery, radiation, or traditional chemotherapy. EMPLICITI IS A TYPE OF IMMUNOTHERAPY THAT IS DIFFERENT FROM TRADITIONAL CHEMOTHERAPY TREATMENTS Unlike traditional chemotherapy treatments, EMPLICITI is a first-of-its-kind immunotherapy medicine that works with your own immune system to fight multiple myeloma. EMPLICITI works in 2 ways. It activates a key type of white blood cell in your immune system, called a Natural Killer (NK) Cell. EMPLICITI also identifies myeloma cells so they are more easily recognized by NK Cells. That way, activated NK Cells can find myeloma cells to destroy. Multiple myeloma cell NK Cell EMPLICITI What are the serious side effects of EMPLICITI? (cont d) Developing new cancers (malignancies) is a risk in patients who receive EMPLICITI with REVLIMID (lenalidomide) and dexamethasone. Your healthcare provider will check you for new cancers during your treatment with EMPLICITI. Talk to your healthcare team to learn more about your risk of developing new cancers if you receive EMPLICITI with REVLIMID and dexamethasone. Please read more Important Facts about EMPLICITI, including serious side effects, on pages 15-16. Visit Empliciti.com to learn more 5

In combination with REVLIMID (lenalidomide) and dexamethasone, EMPLICITI CAN HELP YOUR IMMUNE SYSTEM DESTROY MYELOMA CELLS + = IDENTIFY ACTIVATE DESTROY EMPLICITI identifies myeloma cells so they are easier to find EMPLICITI activates NK Cells Activated NK Cells find myeloma cells to destroy What are the serious side effects of EMPLICITI? (cont d) Liver problems may occur in patients who receive EMPLICITI. Symptoms of liver problems include: yellowing of your skin or eyes confusion tiredness weakness color changes in your stools swelling of the stomach area loss of appetite Your healthcare provider will do blood tests to check your liver function during your treatment with EMPLICITI. Talk to your healthcare team if you have any of the signs and symptoms of liver problems. Please read more Important Facts about EMPLICITI, including serious side effects, on pages 15-16. 6

clinical studies Rick N. EMPLICITI patient What do clinical studies mean for me? Clinical studies can help you understand the potential effects of treatments. How was EMPLICITI studied? EMPLICITI was studied in combination with the medicines REVLIMID (lenalidomide) and dexamethasone and was compared with REVLIMID and dexamethasone alone. All patients in the study had received one to three prior multiple myeloma treatments. + REVLIMID + dexamethasone What should I discuss with my healthcare team before starting EMPLICITI? Talk to your healthcare team about all of your medical conditions, including if you have an infection. Let your healthcare team know as soon as possible if you are a woman who is pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if EMPLICITI can harm an unborn baby. However, REVLIMID may cause birth defects or death of an unborn baby. It is not known if EMPLICITI passes into breastmilk. You should not breastfeed during treatment with EMPLICITI with REVLIMID and dexamethasone. Before receiving EMPLICITI with REVLIMID and dexamethasone females and males must agree to the instructions in the REVLIMID REMS program. The REVLIMID REMS program has specific requirements about birth control (contraception), pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare team to learn more about REVLIMID. Please read more Important Facts about EMPLICITI on pages 15-16. 7

CLINICAL STUDY FOR EMPLICITI WITH REVLIMID (lenalidomide) AND DEXAMETHASONE Rick N. EMPLICITI patient How many people were in the study? 646 There were 646 people with multiple myeloma in the clinical study. All of them had already received at least one other treatment. What was the main goal of the study? The study was designed to look at progression-free survival. Progression-free survival is the length of time during and after treatment of a disease that a patient lives with the disease but it does not get worse. This study was also designed to look at the overall response rate. Overall response rate is the percentage of patients who responded to treatment for example, patients whose level of M protein was lowered by a certain amount. Overall response rates include complete response, very good partial response, and partial response. Visit Empliciti.com to learn more Please read Important Facts about EMPLICITI on pages 15-16. 8

Rick N. EMPLICITI patient What were the results of the study? EMPLICITI in combination with REVLIMID (lenalidomide) and dexamethasone showed, AT 2 YEARS, MORE PEOPLE TAKING EMPLICITI WERE LIVING WITH THEIR DISEASE UNDER CONTROL At 2 years, 41% of people taking EMPLICITI with REVLIMID and dexamethasone were living with their disease under control versus 27% of people taking REVLIMID and dexamethasone alone. 30% LESS RISK OF DISEASE PROGRESSION After at least 2 years of follow-up, people who received EMPLICITI with REVLIMID and dexamethasone were at 30% less risk of their disease getting worse or passing away from any cause than people taking REVLIMID and dexamethasone alone. ~4 OUT OF 5 PEOPLE RESPONDED TO TREATMENT About 4 out of 5 people (78.5%) responded to treatment with EMPLICITI with REVLIMID and dexamethasone compared to about 2 out of 3 people (65.5%) taking REVLIMID and dexamethasone alone. What are the most common side effects of EMPLICITI? fatigue diarrhea fever constipation cough numbness, weakness, tingling, or burning pain in your arms or legs sore throat or runny nose These are not all of the possible side effects of EMPLICITI. Call your doctor for medical advice about side effects. Please read more Important Facts about EMPLICITI on pages 15-16. 9 upper respiratory tract infection decreased appetite pneumonia You can report any side effects you experience to the FDA by calling 1-800-FDA-1088.

Phillip G. What are some possible serious side effects? One of the serious side effects that can occur with EMPLICITI treatment is infusion reactions Infusion reactions can happen during your infusion or within 24 hours after your infusion of EMPLICITI. Before every EMPLICITI infusion, your healthcare team will give you medications to help reduce the risk of infusion reactions. If you have an infusion reaction while receiving EMPLICITI, your healthcare provider will slow or stop your infusion and treat your reaction. If you have a severe infusion reaction your healthcare provider may stop your treatment completely. These are not all of the possible side effects of EMPLICITI. If you have questions, ask your healthcare provider and read other Important Facts about EMPLICITI on pages 15-16 and the Patient Information in the full Prescribing Information here. Tell your healthcare provider or get medical help right away if you have any of these symptoms after your infusion with EMPLICITI: fever chills rash trouble breathing dizziness light-headedness In the clinical study, 1% of patients stopped treatment because of infusion reactions. 10

Phillip G. What are the most common side effects? Most common side effects * Patients taking EMPLICITI with REVLIMID (lenalidomide) and dexamethasone (318 patients) Patients taking REVLIMID and dexamethasone alone (317 patients) fatigue 61.6% (196 patients) 51.7% (164 patients) diarrhea 46.9% (149 patients) 36.0% (114 patients) fever 37.4% (119 patients) 24.6% (78 patients) constipation 35.5% (113 patients) 27.1% (86 patients) numbness, weakness, tingling, or burning pain in your arms or legs cough 34.3% (109 patients) 18.9% (60 patients) 26.7% (85 patients) 20.8% (66 patients) sore throat or runny nose 24.5% (78 patients) 19.2% (61 patients) upper respiratory tract infection 22.6% (72 patients) 17.4% (55 patients) decreased appetite 20.8% (66 patients) 12.6% (40 patients) pneumonia 20.1% (64 patients) 14.2% (45 patients) * These common side effects occurred in 20% or more of patients receiving EMPLICITI in combination with REVLIMID and dexamethasone, and patients taking EMPLICITI with REVLIMID and dexamethasone had a 5% or greater occurrence of these side effects than patients who took REVLIMID and dexamethasone alone. The percentage of patients who stopped treatment due to side effects was similar for both treatment groups (6.0% for patients who received EMPLICITI with REVLIMID and dexamethasone and 6.3% for patients who received REVLIMID and dexamethasone alone). Please read more Important Facts about EMPLICITI on pages 15-16. 11

starting treatment Stella H. How will I receive EMPLICITI? EMPLICITI is given through an intravenous (IV) infusion by your healthcare team. An IV infusion is when medicine is given directly into the bloodstream through a vein usually in the arm, hand, or through an IV port. SCHEDULE APPOINTMENT BRING SOMETHING TO DO RECEIVE EMPLICITI What can I expect at my EMPLICITI appointments? Before infusion: Your healthcare provider will give you medicines before each infusion of EMPLICITI to help reduce the risk of infusion reactions. During infusion: The length of each EMPLICITI infusion will depend on your body weight and how many times you have received EMPLICITI in the past. Talk to your healthcare provider for more information. Please read Important Facts about EMPLICITI on pages 15-16. 12

Stella H. What if I miss my appointment? If you miss your EMPLICITI infusion, call your healthcare team right away to schedule another time to get an infusion. EMPLICITI keeps working between your treatments to help your immune system fight the disease. That s why it s very important to keep every appointment on the day it is scheduled. To make the most of your treatment plan, you should continue receiving EMPLICITI for as long as your healthcare provider prescribes the medication. What are some treatment tips for EMPLICITI? You will be taking other medications as well as EMPLICITI. Filling out personalized treatment calendars along with your healthcare team may help you keep track of the medicine you re taking each day. + + ASK QUESTIONS, TAKE NOTES KNOW YOUR MEDICATIONS KEEP A SCHEDULE Please read Important Facts about EMPLICITI on pages 15-16. 13

Stella H. What do I need to know about my treatment schedule? Your EMPLICITI (elotuzumab) treatment schedule is divided into cycles that are 28 days (4 weeks) long. A cycle is a set number of days you are on treatment and also includes the time you spend resting in between treatments. EMPLICITI is usually given one time every week for cycles 1 and 2 (28-day cycles), and one time every 2 weeks for cycles 3 and up (28-day cycles). REVLIMID (lenalidomide) and dexamethasone are also given during these cycles as part of the treatment. Before each infusion, your healthcare provider will give you medicines to help reduce the risk of an infusion reaction. Your healthcare provider will also decide how many treatments you will receive. CYCLES 1 & 2 (28 S EACH) EMPLICITI REVLIMID ORAL DEXAMETHASONE 1 1 8 8 S 1-21 15 15 22 22 S 23-28 REST PERIOD CYCLES 3 & UP (28 S EACH) EMPLICITI REVLIMID ORAL DEXAMETHASONE 1 1 8 S 1-21 15 15 22 S 23-28 REST PERIOD Take your dose of dexamethasone exactly as prescribed. Keep in mind the dose of oral dexamethasone may vary based on whether EMPLICITI is given that day. Please read Important Facts about EMPLICITI on pages 15-16. 14

Important Facts About EMPLICITI This is a summary of important information that you need to know about EMPLICITI. Your healthcare team can work with you to help answer any questions you may have about EMPLICITI. Keep this information in a safe place, so you can refer to it before and during your treatment. Look out for these icons as you read: Talk to your healthcare team Call a healthcare provider right away Helpful information to remember What is EMPLICITI? EMPLICITI is a prescription medicine used to treat multiple myeloma in combination with other medications: EMPLICITI (elotuzumab) REVLIMID + + (lenalidomide) Remember to read the safety information for the other medications you are receiving. What are the possible side effects of EMPLICITI? dexamethasone EMPLICITI is for patients who have received one to three prior treatments for their multiple myeloma. EMPLICITI is for adults. The safety and effectiveness of EMPLICITI has not been studied in children. EMPLICITI may cause side effects, some of which can be serious. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI. Serious side effects Infusion reactions can happen during your EMPLICITI infusion or within 24 hours after your infusion. Symptoms of an infusion reaction may include: fever chills rash trouble breathing dizziness light-headedness Before every EMPLICITI infusion, your healthcare team will give you medications to help reduce the risk of infusion reactions. If you have an infusion reaction while receiving EMPLICITI, your healthcare provider will slow or stop your infusion and treat your reaction. If you have a severe infusion reaction your healthcare provider may stop your treatment completely. Call your healthcare provider or get medical help right away if you have any of the above symptoms after your infusion with EMPLICITI. Infections may develop in patients who receive EMPLICITI with REVLIMID and dexamethasone, and can be serious. Symptoms of an infection may include: fever flu-like symptoms cough shortness of breath burning with urination painful skin rash Call a healthcare provider right away if you have any of the signs and symptoms of an infection. Developing new cancers (malignancies) is a risk in patients who receive EMPLICITI with REVLIMID and dexamethasone. Your healthcare provider will check you for new cancers during your treatment with EMPLICITI. Talk to your healthcare team to learn more about your risk of developing new cancers if you receive EMPLICITI with REVLIMID and dexamethasone. Continued on next page. 15

Serious side effects (cont d) Liver problems may occur in patients who receive EMPLICITI. Symptoms of liver problems include: tiredness weakness loss of appetite yellowing of your skin or eyes color changes in your stools confusion swelling of the stomach area Your healthcare provider will do blood tests to check your liver function during your treatment with EMPLICITI. Talk to your healthcare team if you have any of the signs and symptoms of liver problems. The most common side effects fatigue diarrhea fever constipation cough numbness, weakness, tingling, or burning pain in your arms or legs sore throat or runny nose upper respiratory tract infection decreased appetite pneumonia These are not all of the possible side effects of EMPLICITI. Call your doctor for medical advice about side effects. You can report any side effects you experience to the FDA by calling 1-800-FDA-1088. What should I discuss with my healthcare team before starting EMPLICITI? Talk to your healthcare team about all of your medical conditions, including if you have an infection. Let your healthcare team know as soon as possible if you are a woman who is pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if EMPLICITI can harm an unborn baby. However, REVLIMID (lenalidomide) may cause birth defects or death of an unborn baby. It is not known if EMPLICITI passes into breastmilk. You should not breastfeed during treatment with EMPLICITI with REVLIMID and dexamethasone. Before receiving EMPLICITI with REVLIMID and dexamethasone females and males must agree to the instructions in the REVLIMID REMS program. The REVLIMID REMS program has specific requirements about birth control (contraception), pregnancy testing, blood donation, and sperm donation that you need to know. Talk to your healthcare team to learn more about REVLIMID. Interactions with other drugs may affect the way EMPLICITI works in your body. Talk to your healthcare team about all of the medicines you are taking before starting EMPLICITI, including: prescription medicines over-the-counter medicines vitamins herbal supplements Please click here to read the Patient Information in the Full Prescribing Information. 16

finding support Debra M. Where can I find help paying for treatment? Bristol-Myers Squibb is committed to helping appropriate patients get access to our medications. We have created BMS Access Support to help you understand your insurance coverage and how you are going to pay for your medicine. We offer an Oncology Co-Pay Program that assists with out-of-pocket co-payment or co-insurance requirements for eligible, commercially insured patients who have been prescribed certain Bristol-Myers Squibb oncology products, including EMPLICITI (elotuzumab). Ask your doctor for more information, visit www.bmsaccesssupport.com, or schedule a call from a BMS Access Support Care Coordinator at 1-800-861-0048 from 8 am to 8 pm ET, Monday to Friday. Where can I find transportation assistance? You may be able to find help arranging transportation to and from medical appointments. Please contact the organizations listed in the next section for more information about programs in your area, and to find out if you are eligible for their services. We re here to help you find the information you need. For additional questions or concerns, call 1-844-EMPLICITI (1-844-367-5424) 8 am to 8 pm ET, Monday to Friday, or visit Empliciti.com. 17

HELPFUL ORGANIZATIONS Myeloma support resources: International Myeloma Foundation 800.452.CURE (2873) www.myeloma.org Cancer support resources: American Cancer Society (ACS) 1.800.227.2345 www.cancer.org/cancer/multiplemyeloma The Multiple Myeloma Research Foundation (MMRF) 203.229.0464 www.themmrf.org The Leukemia & Lymphoma Society (LLS) 914.949.5213 www.lls.org The Myeloma Beacon www.myelomabeacon.com MMORE 1.888.486.4240 www.mmore.org CancerCare, Inc. 800.813.HOPE (4673) www.cancercare.org Cancer Support Community 202.659.9709 www.cancersupportcommunity.org National Cancer Institute (NCI) 1.800.4.CANCER (226237) www.cancer.gov These organizations may help you find support near you. For additional questions or concerns, call 1-844-EMPLICITI (1-844-367-5424) or visit Empliciti.com. Please remember that the first and best resource for any questions or concerns you may have about living with multiple myeloma is your healthcare team. Bristol-Myers Squibb is not affiliated with nor endorses these organizations and the contact information above does not suggest endorsement. 18

GLOSSARY Dexamethasone: A steroid used in the treatment of multiple myeloma, often in combination with other medications. To learn more about dexamethasone, ask your healthcare team. Immunotherapy: A type of treatment that works with your immune system to help control certain cancers. It is different because it is not surgery, radiation, or traditional chemotherapy. M protein: A type of protein made by myeloma cells. M protein levels may be used to estimate the extent of myeloma disease, and measuring them is one way to evaluate response to myeloma treatments. Natural Killer (NK) Cell: A type of white blood cell that helps fight infection or disease and can be important for destroying cancerous cells. Overall response rate: The percentage of patients who responded to treatment for example, patients whose level of M protein was lowered by a certain amount. Overall response rates include complete response, very good partial response, and partial response. Progression-free survival: The length of time during and after treatment of a disease that a patient lives with the disease but it does not get worse. REVLIMID (also known as lenalidomide): An oral medication with anti-myeloma effects. It is used in combination with other medications. To learn more about REVLIMID, ask your healthcare team. Please read Important Facts about EMPLICITI on pages 15-16. 19

NOTES/QUESTIONS FOR MY HEALTHCARE TEAM: Please click here to read the Patient Information in the Full Prescribing Information. EMPLICITI and the related logo are trademarks and Access Support is a registered trademark of Bristol-Myers Squibb Company. REVLIMID and REVLIMID REMS are registered trademarks of Celgene Corporation. 2016 Bristol-Myers Squibb Company. All rights reserved. 689US1502723-05-03 07/16